Health Technology

Astellas Pharma, Inc.

In the news

Quit-smoking app greenlighted as Japan's first digital therapeutic Jun 20, 2020
With profits rolling in, corporate Japan trims its workforce Feb 9, 2020
Astellas joins US startup to create tiny diagnostic implants Sep 17, 2019
Japan's bigger companies slash tax bills to record low Aug 24, 2019
China's big data draws Big Pharma Aug 1, 2019

See more articles on Astellas Pharma, Inc.

Business Summary

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	1,296.16B	11,534.50M
Gross Profit	1,014.87B	9,031.29M
Operating income	220,021M	1,957.95M
Income before tax	156,397M	1,391.77M
Net income	124,086M	1,104.23M
EBITDA	299,705M	2,667.06M
Diluted EPS	67.05	0.59
Dividends Per Share	50	0.44
Total Assets	2,332.39B	19,216.43M
Total liabilities	872,086M	7,185.05M
Total equity	1,460.30B	12,031.37M
Operating cash flow	258,160M	2,297.35M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	1,300.31B	1,306.34B	1,300.84B	1,249.52B	1,296.16B
Gross Profit	970,228M	979,086M	1,002.94B	979,702M	1,014.87B
Operating income	271,241M	280,141M	279,419M	250,897M	220,021M
Income before tax	218,113M	248,967M	247,010M	144,846M	156,397M
Net income	164,679M	222,265M	195,411M	120,589M	124,086M
EBITDA	336,104M	343,599M	345,815M	323,549M	299,705M
Diluted EPS	81.02	114.94	104.07	64.89	67.05
Dividends Per Share	36	38	40	42	50
Total Assets	1,858.20B	1,897.64B	2,315.16B	2,273.62B	2,332.39B
Total liabilities	589,916M	639,252M	1,026.00B	887,514M	872,086M
Total equity	1,268.28B	1,258.39B	1,289.16B	1,386.11B	1,460.30B
Operating cash flow	314,463M	261,428M	224,060M	307,880M	258,160M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	11,732.27M	11,780.07M	11,964.43M	11,781.61M	11,534.50M
Gross Profit	8,754.00M	8,828.97M	9,224.49M	9,237.46M	9,031.29M
Operating income	2,447.30M	2,526.19M	2,569.94M	2,365.67M	1,957.95M
Income before tax	1,967.95M	2,245.07M	2,271.86M	1,365.73M	1,391.77M
Net income	1,485.83M	2,004.28M	1,797.28M	1,137.01M	1,104.23M
EBITDA	3,032.54M	3,098.42M	3,180.61M	3,050.69M	2,667.06M
Diluted EPS	0.73	1.03	0.95	0.61	0.59
Dividends Per Share	0.32	0.34	0.36	0.39	0.44
Total Assets	17,472.54M	17,144.58M	21,445.68M	20,575.81M	19,216.43M
Total liabilities	5,546.92M	5,775.41M	9,503.95M	8,031.80M	7,185.05M
Total equity	11,925.61M	11,369.16M	11,941.71M	12,544.02M	12,031.37M
Operating cash flow	2,837.28M	2,357.44M	2,060.78M	2,902.95M	2,297.35M

Valuation Measures

Mar 2022
PER	28.48
ROA	5.38%
ROE	8.71%
Operating margin	16.97%
Profit margin	9.57%

Key executives

Chairman, President & Chief Executive Officer: Kenji Yasukawa
Chief Financial Officer: Minoru Kikuoka
Chief Scientific Officer: Yoshitsugu Shitaka
Head-Business Administration & Compliance: Fumiaki Sakurai
VP, Head-Oncology Therapeutic Area in Mktg Strat: Peter Sandor

Shareholders

Nomura Asset Management Co., Ltd. (6.2%)
Wellington Management Co. LLP (4.2%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.4%)
Nikko Asset Management Co., Ltd. (3.3%)
Daiwa Asset Management Co. Ltd. (2.8%)
Nippon Life Insurance Co. (2.8%)
The Vanguard Group, Inc. (2.6%)
BlackRock Fund Advisors (1.8%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (1.5%)
Norges Bank Investment Management (1.5%)

Contact Details

Website:http://www.astellas.com
Address: 2-5-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8411, Japan
Phone: +81.3.3244.3000

Related Companies

Astellas Pharma, Inc. /5 Legacy Products/
Astellas Pharma, Inc. /Milrila Injection Product/
OSI Pharmaceuticals, LLC
Representative Office of Astellas Pharma Singapore
Astellas Pharma Malaysia Sdn. Bhd.
Astellas Green Supply, Inc.
Xyphos Biosciences, Inc.
Iota Biosciences, Inc.
Astellas Pharma, Inc. /Agensys Research Facilities/
Astellas Pharma, Inc. /16 Long Listed Products/
Astellas Farma Colombia
Astellas Pharma Director Incentive Plan
Quethera Ltd.
PT Astellas Pharma Indonesia
Astellas Pharma ZAO
Astellas Pharma Hong Kong Co., Ltd.
Astellas Pharma India Pvt Ltd.
Astellas Pharma (Thailand) Co., Ltd.
Astellas Pharma Australia Pty Ltd.
Astellas Pharma Singapore Pte Ltd.
Astellas Pharma Tech Co., Ltd.
Astellas Gene Therapies, Inc.
Mitobridge, Inc.
Astellas Pharma China, Inc.
Perseid Therapeutics LLC
GPDC Partnership
Astellas Pharma Philippines, Inc.
Astellas Pharma Co. Ltd.
Astellas Pharma Canada, Inc.
Fujisawa Taiwan Co. Ltd.

Competitors

AstraZeneca PLC
JW Holdings Corporation
Lantern Pharma, Inc.
Alembic Pharmaceuticals Limited
AbClon, Inc.
Ipsen SA
Eledon Pharmaceuticals, Inc.
DexTech Medical AB
Poseida Therapeutics, Inc.
OSE Immunotherapeutics SA
ADC Therapeutics Ltd
MedPacto, Inc.
Bicycle Therapeutics Plc Sponsored ADR
Golden Biotechnology Corp.
Agenus Inc.
DongKoo Bio & Pharm Co. Ltd.
LegoChem Biosciences, Inc.
Akebia Therapeutics, Inc.
Cullinan Oncology, Inc.
Editas Medicine, Inc.
ERYTech Pharma SA
Keros Therapeutics, Inc.
Kura Oncology, Inc.
Synthetic Biologics, Inc.
Foresee Pharmaceuticals Co., Ltd.
GlycoMimetics, Inc.
LogicBio Therapeutics, Inc.
Aptevo Therapeutics Inc
Cyclerion Therapeutics,Inc.
ImmunoGen, Inc.

Last Updated on 10 Aug, 2022